T-Mobile's Q4 net income surges 48% to $3B - Breaking The News
Download our appPlay StoreApp Store

T-Mobile's Q4 net income surges 48% to $3B

EPA-EFE/ETIENNE LAURENT

T-Mobile US, Inc. announced on Wednesday that it had posted $66.2 billion in service revenue for the 2024 fiscal year and $16.9 billion for the fourth quarter, both leading the industry.

On the other side, net income reached $11.3 billion for 2024, a 36% increase from the previous year, while fourth-quarter net income stood at $3.0 billion, up 48% from the same period in 2023. Earnings per share (EPS) rose 39% to $9.66 for the full year and $2.57 for the quarter. The company also reported record-breaking customer growth in the 12 months, adding 6.1 million postpaid customers, the highest in the industry.

"In 2024, more new postpaid customers chose the Un-carrier than ever before, and we had our lowest ever full-year postpaid phone churn, leading to our third year of more than 3 million postpaid phone net additions," Mike Sievert, CEO of T-Mobile, said.

After the financial results, T-Mobile's shares jumped almost 7% in the premarket in New York.

Related News
Harris slams Trump for 'admiring dictators'
United States Vice President Kamala Harris, the Democratic presidential nominee, spoke in a recent NBC News interview about the choice Americans face in the upcoming election. She contrasted herself with former President Donald Trump, saying that voters must decide whether they want a leader who she claims openly admires authoritarian figures or not. "The American people are being presented with a choice here about whether we want a president who...
Moderna sued for patent infringement over COVID-19 vaccines
Northwestern University launched a lawsuit against Modern Inc. in Delaware federal court, accusing it of using the university's innovations to roll out its COVID-19 vaccine, Spikevax, without a license.Northwestern stressed that Moderna completed the first clinical trial of its COVID-19 vaccine a month before the World Health Organization declared the coronavirus outbreak a pandemic, adding that the pharmaceutical company "could not have achieved this...
Moderna gets greenlight for updated COVID jab
Moderna Inc. shared on Tuesday that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its updated coronavirus vaccine, which targets the JN.1 variant of SARS-CoV-2."COVID-19 continues to present a serious health risk. Updated vaccines targeting circulating strains play a vital role in helping to protect those most at risk from severe illness and hospitalization, alleviating strain on the NHS," Britain's...
FDA greenlights updated Novavax COVID vaccine
The United States Food and Drug Administration (FDA) approved on Friday the emergency use of the Novavax COVID-19 vaccine for "individuals 12 years of age and older." The approval allows those previously vaccinated to receive one dose, while those who haven't been vaccinated will need two. Similar to the Moderna and Pfizer vaccines, this updated version specifically targets the omicron variant JN.1 of the virus while providing increased protection against...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.